VIII factors for the treatment of type A hemophilia

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8623824
APP PUB NO 20100311659A1
SERIAL NO

12528379

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to improved human FVIII variants having at least one substitution in the A2 and/or C2 domain. The present invention also relates to their uses in the treatment of hemophilia A, particularly in patients with inhibitors.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
BIOMETHODES91030 EVRY
HOSPICES CIVILS DE LYON3 QUAI DES CELESTINS LYON 69002

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Blesa, Stephane Grisy-suisnes, FR 3 8
Delcourt, Marc Paris, FR 18 24
Marin, Sylvie Communay, FR 1 1
Menguy, Thierry Gif sur Yvette, FR 6 5
Negrier, Claude Irigny, FR 9 58
Plantier, Jean-Luc Gringy, FR 12 33
Saboulard, Didier Saint Gaudens, FR 1 1

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 7, 2025
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00